News

News

07/06/2019
- As previously announced, BRAFTOVI combinations showed statistically significant improvement in OS and ORR versus control - - Data supports potential to be the first chemotherapy-free, targeted regimen for BRAF-mutant mCRC patients - - Results were presented in an oral presentation today, July 6,
06/25/2019
BOULDER, Colo. , June 25, 2019 /PRNewswire/ --   Array BioPharma Inc. (Nasdaq: ARRY) announced that it will present updated data from the combination of BRAFTOVI ® (encorafenib), a BRAF inhibitor, MEKTOVI ®  (binimetinib), a MEK inhibitor, and ERBITUX ®  (cetuximab), an anti-EGFR antibody (BRAFTOVI
06/17/2019
— Proposed acquisition strengthens Pfizer’s innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term — Opportunity to strengthen category leadership in Oncology with the addition of a breakthrough combination of BRAF/MEK inhibitors
05/29/2019
- Consistent with prior readouts, BRAFTOVI + MEKTOVI demonstrates 33.6 months median overall survival with longer median follow up over 48 months - - Landmark analysis estimates 47% and 39% of patients alive at 3 and 4 years, respectively - - Oral poster presentation June 3, 2019 - BOULDER, Colo.
05/21/2019
- BRAFTOVI combinations showed statistically significant improvement in ORR and OS versus control - - BRAFTOVI + MEKTOVI + cetuximab reduced the risk of death by 48% versus control - - Potential to be the first chemotherapy-free, targeted regimen for metastatic CRC patients - - Array intends to
Displaying 1 - 10 of 16